Vanderkerken K - Search Results

1

A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.

Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, Chai RC, De Veirman K, Owen KL, Opperman KS, Vandyke K, Clark JR, Seckinger A, Kovacic N, Nguyen A, Mohanty ST, Pettitt JA, Xiao Y, Corr AP, Seeliger C, Novotny M, Lasken RS, Nguyen TV, Oyajobi BO, Aftab D, Swarbrick A, Parker B, Hewett DR, Hose D, Vanderkerken K, Zannettino ACW, Amit I, Phan TG, Croucher PI. Khoo WH, et al. Among authors: vanderkerken k. Blood. 2019 Jul 4;134(1):30-43. doi: 10.1182/blood.2018880930. Epub 2019 Apr 25. Blood. 2019. PMID: 31023703 Free article.

2

Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis.

Asosingh K, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Blood. 2003 Apr 15;101(8):3136-41. doi: 10.1182/blood-2002-10-3000. Epub 2002 Dec 12. Blood. 2003. PMID: 12480692 Free article.

3

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, Croucher P. Vanderkerken K, et al. Cancer Res. 2003 Jan 15;63(2):287-9. Cancer Res. 2003. PMID: 12543775

4

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

Croucher PI, Shipman CM, Van Camp B, Vanderkerken K. Croucher PI, et al. Among authors: vanderkerken k. Cancer. 2003 Feb 1;97(3 Suppl):818-24. doi: 10.1002/cncr.11125. Cancer. 2003. PMID: 12548581 Free article.

5

Multiple myeloma biology: lessons from the 5TMM models.

Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Vanderkerken K, et al. Immunol Rev. 2003 Aug;194:196-206. doi: 10.1034/j.1600-065x.2003.00035.x. Immunol Rev. 2003. PMID: 12846816 Review.

6

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Blood. 2004 Apr 15;103(8):3131-7. doi: 10.1182/blood-2003-08-2946. Epub 2003 Nov 26. Blood. 2004. PMID: 15070695 Free article.

7

Evidence of a role for RANKL in the development of myeloma bone disease.

De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI. De Leenheer E, et al. Among authors: vanderkerken k. Curr Opin Pharmacol. 2004 Aug;4(4):340-6. doi: 10.1016/j.coph.2004.03.011. Curr Opin Pharmacol. 2004. PMID: 15251126 Review.

8

Myeloma cells (5TMM) and their interactions with the marrow microenvironment.

Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K. Menu E, et al. Among authors: vanderkerken k. Blood Cells Mol Dis. 2004 Sep-Oct;33(2):111-9. doi: 10.1016/j.bcmd.2004.04.012. Blood Cells Mol Dis. 2004. PMID: 15315788 Review.

9

Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.

Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, Devy L, Noël A, De Bruyne E, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K. Van Valckenborgh E, et al. Among authors: vanderkerken k. Am J Pathol. 2004 Sep;165(3):869-78. doi: 10.1016/S0002-9440(10)63349-4. Am J Pathol. 2004. PMID: 15331411 Free PMC article.

10

The 5T2MM murine model of multiple myeloma: maintenance and analysis.

Vanderkerken K, Asosingh K, Willems A, De Raeve H, Couck P, Gorus F, Croucher P, Van Camp B. Vanderkerken K, et al. Methods Mol Med. 2005;113:191-205. doi: 10.1385/1-59259-916-8:191. Methods Mol Med. 2005. PMID: 15968104

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page